Advanced Biomed Inc. Reports Increased Net Loss and Decreased Total Assets for Q3 2025

Advanced Biomed Inc. reported its financial results for the three-month period ending September 30, 2025, revealing a net loss of $386,901, compared to a loss of $265,580 for the same period in 2024. The company's total operating expenses for the quarter were $523,914, slightly higher than the $520,027 recorded in the previous year. Research and development expenses increased by 30% to $235,992, reflecting heightened clinical development activities. General and administrative expenses decreased by 15% to $287,922, primarily due to reduced staff costs and miscellaneous expenses.

In terms of financial position, Advanced Biomed's total assets decreased to $6,242,970 as of September 30, 2025, down from $6,512,343 at the end of June 2025. Current assets also fell to $5,844,133, while current liabilities rose to $3,044,952, resulting in a working capital surplus of $2,799,181, down from $3,143,443 in the prior quarter. The company had cash reserves of $2,656,519 at the end of the reporting period, a decrease from $2,903,915 at the end of June 2025.

Strategically, Advanced Biomed has been focusing on the development of its oncology products, including the A+LCGuard Lung Cancer Early Screening Kit, which is set to begin clinical research in January 2026. The company has also made significant organizational changes, including the transfer of certain subsidiaries to improve operational efficiency. Notably, the company completed its initial public offering in March 2025, raising approximately $5.49 million in net proceeds, which has been crucial for funding its ongoing operations.

Operationally, Advanced Biomed has not yet commenced sales of its products, and it does not expect to generate revenue until it completes clinical development and receives regulatory approvals. The company is actively pursuing geographic expansion, with plans to establish operations in North America and Europe by early 2026. As of September 30, 2025, the company had 21,640,000 shares of common stock outstanding, reflecting a reverse stock split that took place in October 2024.

Looking ahead, Advanced Biomed acknowledges substantial doubt regarding its ability to continue as a going concern, given its ongoing losses and cash outflows from operating activities. The company is exploring various funding options, including raising additional capital and securing financial support from related parties. Management remains committed to monitoring its financial health and taking necessary actions to secure additional financing as needed.